ESTRO 2024 - Abstract Book

S1566

Clinical - Lower GI

ESTRO 2024

Results:

A total of 789 LARC patients were analyzed: 582 old and 207 young. The median follow-up period was 98.4 month. 88% of patients under 50 years old at the diagnosis belonged to the bad or advanced risk groups with an equal division. In old patients, 85% belonged to the bad or advanced group with a clear dominance of the advanced risk class. Overall survival at 5 and 10 years in the entire population was 78.9% (IC 95% 75.9 – 82.1) and 65.2% (IC 95% 61.3 – 69.5), respectively. Figure 1 The 3-year and 5-year OS resulted in 85% and 78% in the Under 50 group and 76% and 59% in the Over 50 group, respectively. Figure 2 Univariate ESMO risk analysis showed a significant impact on OS (p < 0.001). In multivariate analysis, the Likelihood ratio test showed that OS decreases with increasing age and ESMO risk group (p<0.001). The other variables were not significant. Disease free survival (DFS) at 2 and 5 years in the entire population was 80.2% (IC 95% 77.3 – 83.3) and 70% (IC 95% 66.5 – 73.7), respectively. 55 years old was the cutoff age to significantly separate the two curves (p = 0.02). Figure 3 The 2-year and 5-year DFS in both Under and Over 55 groups were 85.3% and 77.4% and 75.8% and 66.7%, respectively. In multivariate analysis, the Likelihood ratio test showed that DFS decreases with increasing age and ESMO risk group (p<0.004). The other variables were not significant. Metastatic patients at diagnosis represented 7.2% of patients under 50 years of age and 7.5% of those over 50, respectively. As for the DFS, the two curves separated significantly (p = 0.009) at 55 years of age (Figure 9), with a prevalence of metastasis development in the over 55 group. The results for local control were not significant, as there were few local recurrence events. In the overall sample, LC at 2 years was 96.1% (CI 94.7-85.7) and at 5 years was 91.3% (CI 89-93.7).

Conclusion:

In the present study we found that young patients with LARC seems to have a better survival outcome (OS, DFS and OS). ESMO risk group confirmed age as an important factor for survival benefits. It would be useful to conduct a multicenter prospective study including genomic and clinical information to evaluate tolerance and treatment adherence in the two subsets.

Keywords: Young age, rectal cancer, outcomes

3057

Poster Discussion

Clinical impact of ESMO guidelines adherence in rectal cancer: a process mining of Real World Data

Silvia Di Franco 1 , Giuditta Chiloiro 1 , Mariachiara Savino 2 , Isabella Costamagna 1 , Angela Romano 1 , Elisa Meldolesi 1 , Andrea Damiani 3 , Vincenzo Valentini 1 , Maria Antonietta Gambacorta 1 1 Fondazione Policlinico Universitario A. Gemelli - IRCCS, Radiation Oncology, Rome, Italy. 2 Università Cattolica del Sacro Cuore, Radiation Oncology, Rome, Italy. 3 Fondazione Policlinico Universitario A. Gemelli - IRCCS, Gemelli Generator Real World Data, Rome, Italy

Purpose/Objective:

Colorectal cancer is a significant global health problem. To standardise and optimise patient care, advances in treatment methods have been incorporated into clinical guidelines such as those provided by the European